Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  30.00 2.79% 1,105.00 41,787 16:35:26
Bid Price Offer Price High Price Low Price Open Price
1,050.00 1,110.00 1,080.00 1,075.00 1,075.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -10.61 -16.00 798
Last Trade Time Trade Type Trade Size Trade Price Currency
16:39:11 O 20,000 1,095.00 GBX

Renalytix (RENX) Latest News (3)

More Renalytix News
Renalytix Investors    Renalytix Takeover Rumours

Renalytix (RENX) Discussions and Chat

Renalytix (RENX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Renalytix trades in real-time

Renalytix (RENX) Top Chat Posts

DateSubject
25/7/2021
09:20
Renalytix Daily Update: Renalytix Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix was 1,075p.
Renalytix Plc has a 4 week average price of 925p and a 12 week average price of 925p.
The 1 year high share price is 1,220p while the 1 year low share price is currently 415p.
There are currently 72,224,786 shares in issue and the average daily traded volume is 80,650 shares. The market capitalisation of Renalytix Plc is £798,083,885.30.
11/7/2021
18:13
busterdog2: Probably best to avoid then until all the figures make for good reading..... and the share price is considerably higher.
26/6/2021
07:11
wan: I note yesterday Renalytix issued and allotted 150,000 ordinary shares of 0.25 pence each in the share capital of the Company ("Ordinary Shares") following an exercise of options on 24 June 2021. And the sale by Fergus Fleming, CTO, of 15,000 shares at a price of 1075 pence per share. Cardifblue...Renalytix are currently assuming that the FDA process will be complete in the second half of this 2021 calendar year, so some time between now and the end of the year. In my view, there is solid underlying demand for the shares as Renalytix will continue to deliver over the remainder of this calendar year - "We expect the pace of milestone events to continue into the first half of fiscal 2022 beginning in this July, including a potential FDA clearance, additional major health system partnership announcements, beginning operations in the VA medical system, increasing our portfolio of real world evidence data, particularly at the all important primary care level, potential national Medicare coverage determination, and an acceleration in KidneyIntelX testing volumes. With the recent Atrium, Wake Forest partnership and the new potential to onboard from 1,293 healthcare facilities in the Veterans Administration Medical System, we remain confident in our previous guidance of 5 to 7 announced major health system partnerships in calendar 2021."
25/6/2021
07:35
wan: I missed yesterdays RNS regarding the name change to Renalytix, which is subtle, but obviously purposeful - Traditional clinical kidney measurements are flawed. Physicians typically look at estimated GFR (glomerular filtration rate) and urinary albumin creatinine ratio levels, but they are inadequate in identifying those select patients who are more likely to experience progressive decline in kidney function. That changes now… with kidney bioprognosis™. Renalytix is the global founder and leader in the new field of bioprognosis for kidney health. We’ve engineered a new solution that successfully enables early-stage, progression risk assessment, when it counts the most. hTTps://renalytix.com/solutions/ NEW YORK, June 24, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces it has changed its name to Renalytix Plc. The Board believes that the new name reflects the fact the Group is focused on bioprognosis for kidney health, engineering a solution that successfully enables early-stage, progression risk assessment for patients with kidney disease. hTTps://uk.advfn.com/stock-market/london/renalytix-ai-RENX/share-news/Renalytix-AI-PLC-Change-of-name/85437790
15/6/2021
15:06
wan: Just listened to the excellent and very informative conference call. My impression is that managements confidence is very high indeed, but a good slug of restraint is also being deployed. During the call James McCullough discussed that previously he would not allow fixed overheads to build e.g. key hires to drive its commercialization strategy in the United States......until payment was secured or there was a clear line-of-sight on revenues. Recent news says quite a lot then in this regard - Renalytix AI PLC Key new hires to drive commercialization strategy 07/06/2021 NEW YORK and SALT LAKE CITY, June 7, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces a series of key hires to drive its commercialization strategy in the United States market in light of the recently announced Federal Government General Service Administration payment contract and additional large healthcare system partnerships. The combined background and experience of the new leadership team is expected to drive adoption of the KidneyIntelX testing and care model implementation in early-stage diabetic kidney disease populations. Renalytix expects to continue expanding its sales, marketing, and implementation teams with expected KidneyIntelX roll-out beginning in the VA Medical Health System in the 2(nd) half of 2021, and as the Company positions for a broader national expansion beginning in fiscal 2022 in line with expectations for a national Medicare insurance coverage determination later this year. Full release - hTTps://uk.advfn.com/stock-market/london/renalytix-ai-RENX/share-news/Renalytix-AI-PLC-Key-new-hires-to-drive-commercial/85294476 From what I can gather, expansion of the team continues! I am also very optimistic regarding pharma partnerships given the increasing in-bound enquiries being received by Renalytix, and thus the expectation of a growing pharma services revenue line going forwards. There will be further news updates as we go through the remainder of 2021 e.g. Davita etc.
15/6/2021
07:41
pugugly: Still burning cash but lots of dry powder - Some very impressive contracts signed at apparently good margins - No indication that I can see at a quick gkance when they might become cash flow positive or wheter the growing revenue momentum will enable them to raise further funds - if needed - at a premium to current share price. https://www.investegate.co.uk/renalytix-ai-plc--renx-/rns/financial-results-for-third-quarter-of-fy-2021/202106150700089139B/
25/5/2021
10:06
mr roper: Agree with that, wan. My view is that the management have executed the plan superbly to date. The latest two partnerships seem only just be sinking in Stateside and more and more investors are becoming aware of Renx. Results should be due in the next 10 days. Hopefully we’ll get the first sign of small revenue coming through and it’ll peak the interest of a few more potential investors. If the management execute to plan my expectation is a $10bn mkt cap in 24 mths, as a result I still think Renx is better value now than at 250p. NB I looked at exact sciences earlier...$19bn mkt cap..revenue of $1.4bn last year and loss making.... Imagine a scenario of Renx having revenue of $300-500m but the majority dropping to the bottom line in profit...mkt cap...?
21/5/2021
08:31
wan: I note the CEO sold a small percentage of his holding, which was into strength and a rising share price across two days, when clearly there was notable demand for stock (in the US where the shares were sold the shares finished up at $32.57 equivalent to £11.48 per share). I further note that such selling is strictly limited to specific times much like UK rules - Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, or inside information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future. I am not phased by the sale, nor the alignment with the rule above in terms of not being in possession of non-public information etc, as Renalytix has guided the market to expect further partnerships. From the Half-Year Report - We expect to announce additional partnerships during the current fiscal year ending June 30, 2021. We expect to announce five to seven partnerships before the end of calendar 2021. We believe these additional partnerships could materially increase patient and physician access to KidneyIntelX throughout the course of calendar 2021 in advance of broader insurance coverage. hTTps://investors.renalytixai.com/news-releases/news-release-details/half-year-report-1
23/4/2021
08:18
ramridge: If you overlay the share price chart of RENX (UK) to RNLX (US) over say the last 12 months, you will see a near identical match. What does it mean? Well there is no point in looking at the US for any lead or pointers. They are in sync and that's it.
06/4/2021
19:15
red171: Anyone interested in a tax question in connection with the distribution as a dividend in specie of VRCI shares to us RENX SHs? It seems like a RENX question about distribution rather than a VRCI question. Am I right in thinking that the distribution by RENX of VRCI shares as a dividend in specie is taxable as income, like other dividends, at the amount RENX attributes to VRCI value/number of shares in issue at record date 10 July 59,614,134? Usually a company would issue a dividend voucher to confirm details - where can those details be found? Do we have to wait for YE accounts to see the distribution information after the capital reduction entries that made it possible. If right, the VRCI shares we received without paying would then have a notional capital cost of the dividend value assessed under income tax. & any others received in placing have a CGT cost at what we actually paid out in the placing (20p?) Many thanks in advance
16/1/2021
08:32
donald pond: I just can't make sense of those margins. I had in mind the basic cost was $925 a test, and while we may share a big chunk of that with third parties, surely the margin is still going to be very high?There's a chap on twitter, Dirk Gently, who was also explaining VRCI to me, he knows his stuff and that looks great.I do love the free spin off shares these companies generate. We got one VRCI share we got for each RENX one, so for anyone holding from that time you can add another 70p to the RENX share price to work out where you are.
Renalytix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210725 14:48:52